Navigation Links
Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent
Date:3/29/2008

NATICK, Mass. and CHICAGO, March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of two-year data from more than 7,000 patients in the TAXUS ARRIVE Registry program. The study was designed to evaluate the safety performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System in patients treated in "real-world" practice. Outcomes through two years in the simple- use (single vessel/stent) patient group confirmed the favorable results seen in similar patients enrolled in previous TAXUS randomized clinical trials (the clinical trial cohort). Results in the more complex expanded-use group also continued the expected slightly higher event rates than simple-use patients, but were still favorable through two years compared to the published outcomes of other treatment modalities for such patients. Analysis of the data was presented by John M. Lasala, M.D., Ph.D., at the SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago.

"The extensive ARRIVE data show favorable and consistent outcomes in high- risk groups representing some of the most complex patients and lesions," said Dr. Lasala, Professor of Medicine, Washington University School of Medicine in St. Louis. "Outcomes in the simple-use patients in ARRIVE are consistent with results from the TAXUS Stent cohorts in the TAXUS randomized clinical trial program, indicating that the ARRIVE methodology is very efficient in capturing adverse event outcomes. Overall, then, these results support the long-term performance of the TAXUS Stent across the broad range of patients studied in these trials and registries."

The pooled analysis included two-year outcomes for 7,033 patients in t
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
2. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
3. GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral)
4. Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
7. Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
8. UPDATE: Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
9. Use of Fractional Flow for Optimizing Patient Outcomes is Topic of Several Sessions at TCT 2007
10. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
11. Patient-Reported Outcomes (PROs) Improve Cancer Treatment -- Experts Agree
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014 Research and Markets ... Market by Material, by Application, Geography - Global Analysis ... offering. Organic electronics, also called as ... material science which deals with small conductive molecules and ... small molecules and polymers are carbon based, made using ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
(Date:10/19/2014)... , Oct. 19, 2014 NextCODE Health, which ... whole genome in real time, today announced the launch of ... NextCODE Exchange , at the American Society of Human Genetics ... To learn more, sign up and apply for free beta ... unique features and benefits can be viewed here . ...
Breaking Biology Technology:Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... Mike Byrom, Vince , Pallotta, ... 2130 Woodward Street Austin, TX 78744-1832 * Corresponding authors <A , ... href="mailto:lford@ambion.com">lford@ambion.com , ... , Labeling GAPDH and c-myc siRNA with either fluorescein ...
... Collections of siRNAs targeting , ... cells. To identify genes involved in ... cells can be transfected with different siRNAs and assayed for , ... Cellomics, Inc., who pioneered the field of High Content , ...
... Up to 50X more activity and 350% greater , catalytic efficiency ... DNA that can plague RT-PCR , ... origin: Purified from a source that is 10 7 -fold ... , , ...
Cached Biology Technology:Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 2Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 3Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 4Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 5Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 6Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 7Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 8Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 9Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 10Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 11Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 12Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 13Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 14Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 15Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect 16Using Validated siRNAs in Functional Genomic Assays 2Using Validated siRNAs in Functional Genomic Assays 3TURBO DNase: Hyperactive, Salt Tolerant DNase 2TURBO DNase: Hyperactive, Salt Tolerant DNase 3TURBO DNase: Hyperactive, Salt Tolerant DNase 4TURBO DNase: Hyperactive, Salt Tolerant DNase 5
(Date:10/19/2014)... India over the last 30 years contributed only ... during that time, according to a new study ... ., "Energy access is fundamental to development: it ... education, communication, and health," says IIASA researcher Shonali ... energy access is widely agreed to be an ...
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... When a zebra finch hears a new song from a member ... brain in unexpected ways, researchers report. The sequential switching on and ... tune offers a new picture of memory in the songbird brain. ... the National Academy of Sciences , was a surprise, said principal ...
... Institute,s Xie Lab has revealed how the BAM protein ... involved in regulating the quality of stem cells through ... Early Edition. Maintaining the proper balance between ... homeostasis. An imbalance between the two can lead to ...
... funded will serve aquaculture and papaya farmers as well ... species endangered due to attacks by several species of ... WPTRC, was awarded $186,960 for a genetic variability study ... vannamei, through developing a panel of species-specific microsatellite genetic ...
Cached Biology News:Researchers see evidence of memory in the songbird brain 2Xie Lab uncovers molecular machinery related to stem cell fate 2T-STAR grant funds genetic studies on shrimp and papaya and endangered cycad rescue 2
... hormones which belong to the transforming ... superfamily is a large group of ... aspects of development, reproductive function and ... TGF-s, bone morphogenetic proteins, growth differentiation ...
... Antibody Plate is a 96-well ELISA-compatible ... This antibody (mouse IgG 1 ) ... glutathione-S-transferase (GST), and binds with ... fusion protein in which the tag ...
... Testing Laboratory (RTL) can provide you ... years. ,,Microbial method development and validation ... the conditions of your GMP manufacturing ... products,,We offer a full spectrum of ...
... QED Bioscience has over 23 years of ... lines. We have made antibodies to large ... and viral antigens, and plasmid DNA-encoded antigens. ... is unique, so our hybridoma development programs ...
Biology Products: